胃底腺息肉 中国就医指南

Fundic gland polyp (FGP) is the most common type of gastric polyp, typically arising from the fundus and body of the stomach. These are benign, non-neoplastic lesions composed of dilated, cystically enlarged fundic glands lined by parietal and chief cells—without dysplasia in the vast majority of sporadic cases. FGPs are usually discovered incidentally during upper gastrointestinal endoscopy performed for unrelated indications such as dyspepsia, reflux, or anemia. Pathogenetically, sporadic FGPs are strongly associated with long-term proton pump inhibitor (PPI) use, likely due to PPI-induced hypergastrinemia leading to fundic gland hyperplasia. In contrast, FGPs occurring in the context of familial adenomatous polyposis (FAP) are genetically driven (APC gene mutations) and carry a higher, albeit still low, risk of dysplasia—particularly when larger (>1 cm), numerous (>20), or histologically atypical. Epidemiologically, FGPs are found in approximately 0.8–2.5% of routine upper endoscopies in Western populations and up to 5–8% in patients on chronic PPI therapy; they are more prevalent in middle-aged and older adults (peak incidence 50–70 years), with a slight female predominance. Risk factors include prolonged PPI use (>1 year), age >50, female sex, and—critically—undiagnosed or untreated FAP. While most FGPs are asymptomatic and do not impair quality of life directly, their incidental discovery often triggers patient anxiety about cancer risk, unnecessary repeat endoscopies, and healthcare overutilization. Larger or multiple polyps may rarely cause nonspecific symptoms such as epigastric discomfort or occult gastrointestinal bleeding, but these are uncommon. Importantly, FGPs themselves do not cause functional gastric impairment, nor do they alter digestion or nutrient absorption. However, persistent concern about malignancy, repeated surveillance endoscopies, and potential overtreatment can negatively affect psychological well-being and daily functioning—especially among health-anxious individuals. Management focuses on accurate diagnosis (via high-definition endoscopy with targeted biopsy), risk stratification (sporadic vs. FAP-associated), and judicious surveillance rather than routine resection. Current guidelines (e.g., ACG, ESGE) recommend no removal for typical small (<1 cm), isolated, histologically confirmed sporadic FGPs, reserving endoscopic resection for lesions with suspicious features (size ≥1 cm, irregular surface, ulceration, or dysplasia on biopsy) or in confirmed FAP patients. Patient education regarding the overwhelmingly benign nature of sporadic FGPs—and the importance of evaluating for underlying FAP in young patients or those with multiple polyps—is essential to alleviate distress and optimize long-term outcomes.

# 胃底腺息肉治疗方案与费用明细（消化内科）

一、非手术/保守管理方案

适用于：无症状、直径＜5mm、病理确诊为典型胃底腺息肉（无异型增生）、幽门螺杆菌阴性者。

• •随访监测：胃镜复查（每2–3年）+活检，费用：1,200–1,800元（含普通/无痛胃镜、病理活检、快速尿素酶检测）
• •药物干预（仅限合并HP感染者）：四联根除方案（PPI+铋剂+2种抗生素），疗程10–14天，药费：320–680元（国产仿制药至原研药梯度）
• •基础检查配套：血常规、肝肾功能、胃蛋白酶原Ⅰ/Ⅱ、胃泌素-17，合计：450–620元

二、内镜下切除方案（微创核心治疗）

适用：直径≥5mm、有出血/不适症状、或病理提示轻度异型增生者。

• •EMR（内镜黏膜切除术）：单发息肉，≤10mm，费用：3,800–5,600元（含术前检查、麻醉、EMR操作、术后病理、3日观察）
• •ESD（内镜黏膜下剥离术）：多发、≥10mm或疑似高级别异型增生，费用：6,200–9,500元（含高清染色内镜、专用器械、延长住院）

三、特殊复杂情况处理

• •合并重度异型增生或早期癌变：转外科评估腹腔镜胃局部切除，费用：32,000–48,000元（含MDT会诊、术前分期CT/MRI、手术及5日住院）
• •复发性/弥漫性胃底腺息肉（如家族性腺瘤性息肉病相关）：需长期随访+基因检测（APC基因），检测费：2,600元；年度胃镜监测费：1,500元/次

方案快速选择指南

✅ 预算有限且无症状：选保守随访（首年总支出≈2,200元） ✅ 单发中等大小（6–12mm）：首选EMR（性价比最优，治愈率＞98%） ✅ 多发/形态不规则/伴异型增生：直接ESD，避免漏切与复发 ✅ 已证实癌变或遗传高风险：启动多学科诊疗（MDT），纳入医保特病管理